FDA Approves Merck & Co., Inc.'s Expanded Label for CANCIDAS(R) (caspofungin acetate) as the First and Only Echinocandin Therapy for the Treatment of Pediatric Patients (3 months and older) with Indicated Fungal Infections

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded label for CANCIDAS®, which makes it the first and only echinocandin therapy approved in the United States for the treatment of pediatric patients aged 3 months to 17 years with indicated fungal infections.